Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.

PURPOSE Germline mutations of the gene encoding subunit B of the mitochondrial enzyme succinate dehydrogenase (SDHB) predispose to malignant paraganglioma (PGL). Timely and accurate localization of these aggressive tumors is critical for guiding optimal treatment. Our aim is to evaluate the performance of functional imaging modalities in the detection of metastatic lesions of SDHB-associated PGL. PATIENTS AND METHODS Sensitivities for the detection of metastases were compared between [18F]fluorodopamine ([18F]FDA) and [18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), iodine-123- (123I) and iodine-131 (131I) -metaiodobenzylguanidine (MIBG), 111In-pentetreotide, and Tc-99m-methylene diphosphonate bone scintigraphy in 30 patients with SDHB-associated PGL. Computed tomography (CT) and magnetic resonance imaging (MRI) served as standards of reference. RESULTS Twenty-nine of 30 patients had metastatic lesions. In two patients, obvious metastatic lesions on functional imaging were missed by CT and MRI. Sensitivity according to patient/body region was 80%/65% for 123I-MIBG and 88%/70% for [18F]FDA-PET. False-negative results on 123I-MIBG scintigraphy and/or [18F]FDA-PET were not predicted by genotype or biochemical phenotype. [18F]FDG-PET yielded a by patient/by body region sensitivity of 100%/97%. At least 90% of regions that were false negative on 123I-MIBG scintigraphy or [18F]FDA-PET were detected by [18F]FDG-PET. In two patients, 111In-pentetreotide scintigraphy detected liver lesions that were negative on other functional imaging modalities. Sensitivities were similar before and after chemotherapy or 131I-MIBG treatment, except for a trend toward lower post- (60%/41%) versus pretreatment (80%/65%) sensitivity of 123I-MIBG scintigraphy. CONCLUSION With a sensitivity approaching 100%, [18F]FDG-PET is the preferred functional imaging modality for staging and treatment monitoring of SDHB-related metastatic PGL.

[1]  A. Hogg,et al.  Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Michelle Dusart,et al.  18FDG PET in oncology: the best and the worst (Review). , 2006, International journal of oncology.

[3]  H. Boezen,et al.  Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas--experience and meta-analysis. , 2006, Anticancer research.

[4]  W. Young,et al.  Paraganglioma—All in the Family , 2006 .

[5]  K. Byth,et al.  Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.

[6]  Paul Kinahan,et al.  Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma , 2006 .

[7]  J. Carrasquillo,et al.  Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites , 2006, Nuclear medicine communications.

[8]  S. Richard,et al.  Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Eng,et al.  Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. , 2005, JAMA.

[10]  R. Worrell,et al.  Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. , 2005, European journal of endocrinology.

[11]  I. Ilias,et al.  New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas , 2005, Trends in Endocrinology & Metabolism.

[12]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[13]  J. Carrasquillo,et al.  Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. , 2003, The Journal of clinical endocrinology and metabolism.

[14]  W. Rubinstein,et al.  Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas , 2002, Journal of medical genetics.

[15]  S. Hasegawa,et al.  Metastases of predominantly dopamine-secreting phaeochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose. , 2001, The European journal of surgery = Acta chirurgica.

[16]  J. Doppman,et al.  A "pheo" lurks: novel approaches for locating occult pheochromocytoma. , 2001, The Journal of clinical endocrinology and metabolism.

[17]  S. Larson,et al.  Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[19]  G. Eisenhofer.  The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. , 2001, Pharmacology & therapeutics.

[20]  Graeme Eisenhofer,et al.  6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma , 2001, Hypertension.

[21]  H. Bonjer,et al.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. , 2001, The Journal of clinical endocrinology and metabolism.

[22]  Ulrich Müller,et al.  Mutations in SDHC cause autosomal dominant paraganglioma, type 3 , 2000, Nature Genetics.

[23]  E. Pauwels,et al.  Positron-emission tomography with [18F]fluorodeoxyglucose , 2000, Journal of Cancer Research and Clinical Oncology.

[24]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[25]  B. Shulkin,et al.  Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. , 1999, American journal of clinical oncology.

[26]  I. Francis,et al.  Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. , 1999, Radiology.

[27]  E. Krenning,et al.  Octreotide scintigraphy for the detection of paragangliomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  R. Koeppe,et al.  Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. , 1993, Radiology.

[29]  S. Steinberg,et al.  Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. , 1990, Human pathology.

[30]  E. Gelmann,et al.  Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. , 1988, Annals of internal medicine.

[31]  W. Beierwaltes,et al.  Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. , 1985, Radiology.